Zobrazeno 1 - 10
of 196
pro vyhledávání: '"Yusuke Oji"'
Autor:
Fumihiro Fujiki, Soyoko Morimoto, Akiko Katsuhara, Akane Okuda, Saeka Ogawa, Eriko Ueda, Maki Miyazaki, Ayako Isotani, Masahito Ikawa, Sumiyuki Nishida, Hiroko Nakajima, Akihiro Tsuboi, Yoshihiro Oka, Jun Nakata, Naoki Hosen, Atsushi Kumanogoh, Yusuke Oji, Haruo Sugiyama
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Memory T cells play an essential role in infectious and tumor immunity. Vitamin A metabolites such as retinoic acid are immune modulators, but the role of vitamin A metabolism in memory T-cell differentiation is unclear. In this study, we identified
Externí odkaz:
https://doaj.org/article/be408ef12699491a8d81c30d652284b0
Autor:
Yusuke Oji, Naoki Kagawa, Hideyuki Arita, Norifumi Naka, Ken-ichiro Hamada, Hidetatsu Outani, Yasushi Shintani, Yoshito Takeda, Eiichi Morii, Kenzo Shimazu, Motoyuki Suzuki, Sumiyuki Nishida, Jun Nakata, Akihiro Tsuboi, Miki Iwai, Sae Hayashi, Rin Imanishi, Sayaka Ikejima, Mizuki Kanegae, Masahiro Iwamoto, Mayu Ikeda, Kento Yagi, Haruka Shimokado, Hiroko Nakajima, Kana Hasegawa, Soyoko Morimoto, Fumihiro Fujiki, Akira Nagahara, Atsushi Tanemura, Yutaka Ueda, Tsunekazu Mizushima, Masato Ohmi, Takayuki Ishida, Manabu Fujimoto, Norio Nonomura, Tadashi Kimura, Hidenori Inohara, Seiji Okada, Haruhiko Kishima, Naoki Hosen, Atsushi Kumanogoh, Yoshihiro Oka, Haruo Sugiyama
Publikováno v:
Cancers, Vol 15, Iss 2, p 393 (2023)
No standard treatment has been established for most rare cancers. Here, we report a clinical trial of a biweekly WT1 tri-peptide-based vaccine for recurrent or advanced rare cancers. Due to the insufficient number of patients available for a traditio
Externí odkaz:
https://doaj.org/article/0960568eeee148bfaa32da45a26639f7
Autor:
Yoshiko Hashii, Yoshihiro Oka, Naoki Kagawa, Naoya Hashimoto, Hiroyuki Saitou, Syogo Fukuya, Mizuki Kanegae, Sayaka Ikejima, Yusuke Oji, Keiichi Ozono, Akihiro Tsuboi, Haruo Sugiyama
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Diffuse midline glioma (DMG) in children is a highly aggressive, malignant brain tumor that is fatal when relapsed. Wilms tumor 1 (WT1) is a high-priority antigen target for cancer immunotherapy. We hereby report on a pediatric patient who had DMG th
Externí odkaz:
https://doaj.org/article/1d662f20d7d34a838619aa5f8de91774
Autor:
Jun Nakata, Kayako Isohashi, Yoshihiro Oka, Hiroko Nakajima, Soyoko Morimoto, Fumihiro Fujiki, Yusuke Oji, Akihiro Tsuboi, Atsushi Kumanogoh, Naoya Hashimoto, Jun Hatazawa, Haruo Sugiyama
Publikováno v:
Diagnostics, Vol 11, Iss 6, p 1041 (2021)
Assessment of tumor response during treatment is one of the most important purposes of imaging. Before the appearance of immunotherapy, response evaluation criteria in solid tumors (RECIST) and positron emission tomography response criteria in solid
Externí odkaz:
https://doaj.org/article/a4175109914048c59d1b9fef5e02ee8a
Autor:
Chen Wu, Sihan Wang, Caihua Xu, Andreas Tyler, Xingru Li, Charlotta Andersson, Yusuke Oji, Haruo Sugiyama, Yijiang Chen, Aihong Li
Publikováno v:
Cellular Physiology and Biochemistry, Vol 35, Iss 2, Pp 647-662 (2015)
Background: A novel link between oncogenic KRAS signalling and WT1 was recently identified. We sought to investigate the role of WT1 and KRAS in proliferation and apoptosis. Methods: KRAS mutations and WT1 (cMyc) expression were detected using Sanger
Externí odkaz:
https://doaj.org/article/cf33eeb601eb424a8cd889f23fca39e6
Autor:
Keiko Yamanouchi, Tsuyoshi Ohta, Zhiyang Liu, Yusuke Oji, Haruo Sugiyama, Viji Shridhar, Sohei Matsumura, Toshifumi Takahashi, Kazuhiro Takahashi, Hirohisa Kurachi
Publikováno v:
Translational Oncology, Vol 7, Iss 5, Pp 580-589 (2014)
The Wilms' tumor 1 gene WT1 encodes a zinc transcription factor involved in a variety of cancer-related processes. In this study, we sought to investigate the effects of WT1 splice variants on tumorigenic activity and survival in an in vivo ovarian c
Externí odkaz:
https://doaj.org/article/62f5ab95e5e94cc7ad4f901275575768
Publikováno v:
Stem Cells International, Vol 2017 (2017)
Externí odkaz:
https://doaj.org/article/8d8b19b19a384a6a9524fb45706d9c74
Autor:
Kana Hasegawa, Satomi Tanaka, Fumihiro Fujiki, Soyoko Morimoto, Katsuhiko Nakano, Hiroko Kinoshita, Atsushi Okumura, Yuka Fujioka, Rika Urakawa, Hiroko Nakajima, Naoya Tatsumi, Jun Nakata, Satoshi Takashima, Sumiyuki Nishida, Akihiro Tsuboi, Yoshihiro Oka, Yusuke Oji, Eiji Miyoshi, Takako Hirata, Atsushi Kumanogoh, Haruo Sugiyama, Naoki Hosen
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0152326 (2016)
To improve cancer immunotherapy, it is important to understand how tumor cells counteract immune-surveillance. In this study, we sought to identify cell-surface molecules associated with resistance of leukemia cells to cytotoxic T cell (CTL)-mediated
Externí odkaz:
https://doaj.org/article/94c069a8b32e45ffa55603171c95423f
Autor:
Yoshihiro Oka, Akihiro Tsuboi, Olga A. Elisseeva, Hiroko Nakajima, Fumihiro Fujiki, Manabu Kawakami, Toshiaki Shirakata, Sumiyuki Nishida, Naoki Hosen, Yusuke Oji, Ichiro Kawase, Haruo Sugiyama
Publikováno v:
The Scientific World Journal, Vol 7, Pp 649-665 (2007)
Wild-type Wilms' tumor gene WT1 is expressed at a high level in hematopoietic malignancies including acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndromes, as well as in various kinds of solid cancers. Human cytotoxic T lymphocy
Externí odkaz:
https://doaj.org/article/6457d742fe764e12aebea5bff88f45bd
Autor:
Kana Hasegawa, Satomi Tanaka, Fumihiro Fujiki, Soyoko Morimoto, Hiroko Nakajima, Naoya Tatsumi, Jun Nakata, Satoshi Takashima, Sumiyuki Nishida, Akihiro Tsuboi, Yoshihiro Oka, Yusuke Oji, Atsushi Kumanogoh, Haruo Sugiyama, Naoki Hosen
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144594 (2015)
Leukemia differs substantially with respect to stromal milieu from tumors that progress locally as solid masses, and the physiological importance of immunosurveillance in leukemia remains unclear. However, currently available mouse leukemia models ha
Externí odkaz:
https://doaj.org/article/ff5de50689044014ac06fc076c337c5a